Report On Comera Life Sciences Holdings Inc.’s (CMRA) Price Performance


The stock of Comera Life Sciences Holdings Inc. (NASDAQ:CMRA) increased by $1.93 on Tuesday to finish at $3.86, up 100.00 percent. The last five days have seen an average of 11,935,619 shares of common stock traded. The average number of shares traded over the last 20 days was 3,792,285, while the average volume over the last 50 days totaled 3,021,162.

CMRA stock appreciated 40.88% since last month. On 09/06/22, the company’s shares reached a one-month low of $1.5000. The stock touched a high of $15.30, after rallying from a low of $1.11 in 52 weeks. The price of CMRA stock has declined by -61.90%. Still, the stock price is down -74.77% from the 52-week high.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .


Insider Transactions

There have been 2 days since Comera Life Sciences Holdings Inc. (CMRA) last reported insider trading activity on Sep 12. On Sep 12, Director Sherblom James acquired 50,000 shares at $2.03 each. This transaction resulted in the insider spending $101,500. On Sep 09, Hackman Jeffrey S. added 47,600 shares at a price of US$2.06. After the transaction, the insider now owns 47,600 shares. EVP & CFO Campbell Michael Gerard had earlier bought 25,000 shares on Sep 08 for $2.07 a share. The transaction was completed for $51,750.

Valuation Metrics

Comera Life Sciences Holdings Inc. (CMRA) has a trailing price-to-earnings (P/E) ratio of 22.44. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 235.83, the price-to-book (PB) ratio of 0.51.

Financial Health

For the recent quarter, Comera Life Sciences Holdings Inc.’s quick ratio was 0.10, while its current ratio was 0.10, indicating its inability to pay off its debt.

Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. CMRA’s return on assets (ROA) during the last 12 months has been 2.10%. In the meantime, the return on equity (ROE) for the last 12 months was 2.30%.

Earnings Surprise

EBITDA was -$3.97 million for the quarter. At the end of Comera Life Sciences Holdings Inc.’s most recent quarter, its liabilities totaled 3.58 million, while its total debt was $0.41 million. Equity owned by shareholders amounts to $19.09 million.

Technical Picture

Here’s a quick look at Comera Life Sciences Holdings Inc.’s (CMRA) price momentum from a technical perspective. As of 13 September, the RSI 9-day stood at 77.76%, suggesting the stock is Overbought, with a 366.47% historical volatility rate.

The stochastic %K and %D were 47.41% and 34.92% respectively, while the average true range (ATR) was 0.5600. Based on the 14-day stochastic reading of 84.89%, the RSI (14) reading is 69.16%. On the 9-day MACD Oscillator, the stock is at 0.4100, and the 14-day reading is at 0.5000.

Analyst Ratings

Analysts have assigned Comera Life Sciences Holdings Inc. (CMRA) an – rating. CMRA is a stock that is recommended for selling by 0 brokerage firms, while 0 companies recommend holding. The stock is underweighted by 0 analysts. Among the analysts who rate the stock, 0 rates it overweight and 0 others recommend it as a buy.


Please enter your comment!
Please enter your name here